Durect Corporation

Intarcia Therapeutics, Inc.

Corium International, Inc.

Alza Corporation

Corium Corporation

Indivior UK Limited

Other

Corium Pharma Solutions, Inc.

Panther Life Sciences Corporation

Guohua Chen

Parminder Singh

Andrew S Luk

Paul R Houston

Rupal A Ayer

Robert Wade Worsham

Catherine Manya Rohloff

Pauline C Zamora

Danir F Bayramov

Stan Lam

Gunjan H Junnarkar

Zhongli Ding

David T Priebe

Lothar W Kleiner

Joseph Creagan Trautman

Steven Richard Klemm

Danny Lee Bowers

Esi Ghartey-Tagoe

Keith E Dionne

Scott D Lautenbach

Michael A DesJardin

Michael A Desjardin

Andy Klemm

Ashutosh Shastry

Doug Bourne

John J Spaltro

Janet Wendorf

Scott D Jordan

Steve A Berry

Craig I Rodenberger

Steve Williams

Andrew Richard Klemm

Robert M Gale

Jeremy C Wright

Randall G Berggren

Lawton Hom

Gilbert T Tong

Danir Bairamov

Andrew Sheung-King Luk

Danir Bayramov

Danir Bayamov

Teresa Kameda

Roy Bannister

Lothar Walther Kleiner

Paul Ricky Houston

Gunjan Junnarkar

Andy Kelmm

Steven Richard Kelmm

David Priebe

Sahitya Katikaneni

Latha Pisharody Narayanan

Stephen Andrew Berry

Appala Sagi

Jeremy Corwin Wright

A method and a drug delivery system for transdermally administering parathyroid hormone (PTH) in a pulsatile fashion are provided, where the drug delivery system comprises an array of microprojections each comprising PTH.

Method and device for transdermal delivery of parathyroid hormone using a microprojection array

Microstructure arrays and methods for using and manufacturing the arrays are described.

Microarray for delivery of therapeutic agent and methods of use

Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Short duration depot formulations

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a Cto Cratio of less than 200 and a lag time less than 0.2.

Sustained release small molecule drug formulation

Devices and methods for using and manufacturing microstructure arrays having at least a detachable distal area are described.

A microprojection array comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a therapeutic agent that is poorly soluble in water or an aqueous solvent.

Microstructure array, methods of making, and methods of use

A microprojection array comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a therapeutic macromolecule and a stabilizing excipient. Described herein are microstructures having a proximal and distal layer, wherein the distal layer which contains the therapeutic molecule does not rely on the presence of a structure-forming polymer to impart the mechanical strength necessary to penetrate the skin. Methods of forming the array, and methods of using the array are contemplated.

Microarray with polymer-free microstructures, methods of making, and methods of use

In an aspect of the invention, an array of microprotrusions is formed by providing a mold with cavities corresponding to the negative of the microprotrusions, casting atop the mold a first solution comprising a biocompatible material and a solvent, removing the solvent, casting a second solution atop the first cast solution, removing the solvent from the second solution, and demolding the resulting array from the mold. The first solution preferably contains an active ingredient.

Solvent-cast microprotrusion arrays containing active ingredient

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having Cto Cratio less than 200 and lag time less than 0.2.

Growing community of inventors

Sunnyvale, CA, United States of America

Guohua Chen